Lupin’s arm gets USFDA approval for generic Combivir tablets

31 Oct 2011 Evaluate

Pharma Major, Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Lamivudine and Zidovudine tablets, 150 mg/300 mg from the United States Food and Drugs Administration (USFDA) for the company's abbreviated new drug application (ANDA) to market a generic version of Combivir tablets, 150 mg/300 tug of ViiV Healthcare.

Lupin's Lamivudine and Zidovudine tablets are the AB-rated generic equivalent of ViiV Healthcare's Combivir tablets, 150 mg/300 mg. Lamivudine - Zidovudine is a combination of two nucleoside analogue reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

According to IMS Health sales data, Combivir tablets, 150 mg/300 mg had annual US sales of approximately $295 million for the twelve months ending June 2011.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. Lupin has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×